<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817840</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR7901</org_study_id>
    <nct_id>NCT03817840</nct_id>
  </id_info>
  <brief_title>Cushing's Lipodystrophy</brief_title>
  <official_title>Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York Obesity and Nutrition Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and
      metabolism that occur in patients with Cushing's disease. Our objective is to identify the
      mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in
      energy expenditure and metabolism that accompany them. These findings may have important
      implications not only for those with Cushing's disease, but for the millions of Americans who
      are treated with chronic glucocorticoids for an array of clinical conditions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Energy Expenditure</measure>
    <time_frame>Change from baseline REE at 3 months post-treatment</time_frame>
    <description>Resting energy expenditure (REE) will be measured by whole room indirect calorimetry prior to and following cure of Cushing's Disease (CD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total body adipose tissue volume</measure>
    <time_frame>Change in total body adipose tissue volume from baseline at 3 months post-treatment</time_frame>
    <description>Whole body MRI will be utilized to measure total body adipose tissue volume</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cushing's Syndrome</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Treatment of Cushing's</intervention_name>
    <description>Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism</description>
    <other_name>Medical treatment of hypercortisolism</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ACTH-dependent Cushing's syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-70 yrs

          2. Body mass index (BMI) &lt;35 kg/m2

          3. Urine free cortisol (UFC) ≥150ug/d

          4. Pituitary tumor &gt;6mm on MRI or an inferior petrosal sinus sampling with central to
             peripheral plasma adrenocorticotropic hormone (ACTH) gradient

          5. Normal renal and thyroid function

          6. HbA1c ≤8.0.

        Exclusion Criteria:

          1. Smoking

          2. Alcohol &gt;2 drinks/day

          3. Uncontrolled hypertension

          4. HIV given potential for lipodystrophic confounding

          5. Pregnancy and nursing

          6. Use of beta-blockers, β-adrenergic or diabetes medications other than insulin

          7. History of claustrophobia or difficulty lying flat

          8. In-dwelling metal hardware.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabrielle Page-Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabrielle Page-Wilson, MD</last_name>
    <phone>212-305-3725</phone>
    <email>gp2287@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Neuroendocrine Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Page-Wilson, M.D.</last_name>
      <phone>212-305-3725</phone>
      <email>gp2287@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cara Dimino</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gabrielle Page-Wilson</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

